Transthyretin Amyloid CardiomyopathySymptoms, Doctors, Treatments, Advances & More
Learn About Transthyretin Amyloid Cardiomyopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
MUSC Health Cardiology At West Ashley Medical Pavilion
Daniel Judge is a Transplant Surgeon and a Cardiologist practicing medicine in Charleston, South Carolina. Dr. Judge is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy, Cardiac Amyloidosis, Heart Transplant, and Cardiac Ablation. Dr. Judge is currently accepting new patients.
Sanjiv Shah is a Cardiologist practicing medicine in Chicago, Illinois. Dr. Shah is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Failure, Cardiac Amyloidosis, Heart Transplant, and Cardiac Ablation. Dr. Shah is board certified in American Board Of Internal Medicine - Cardiovascular Disease (Certified). Dr. Shah is currently accepting new patients.
Mcv Associated Physicians
Keyur Shah is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist practicing medicine in Richmond, Virginia. Dr. Shah is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Transthyretin Amyloidosis, Primary Amyloidosis, Heart Failure, Heart Transplant, and Thrombectomy. Dr. Shah is currently accepting new patients.
Summary: This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and prelimina...
Summary: This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study...